Results 41 to 50 of about 34,182 (233)

CLINICAL CASE OF TOCILIZUMAB USE IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS

open access: yesПедиатрическая фармакология, 2014
The article presents a case of successful use of a preparation of monoclonal antibodies to interleukin 6 receptors (tocilizumab) at asevere systemic juvenile idiopathic arthritis.
O. L. Lomakina   +4 more
doaj   +1 more source

COVID‐19 Vaccination is not Associated with the Development of Idiopathic Inflammatory Myositis in U.S. Veterans

open access: yesArthritis Care &Research, Accepted Article.
Objective Several case reports have proposed a potential association between COVID‐19 vaccination and the subsequent development of idiopathic inflammatory myositis (IIM). This study examined prior COVID‐19 vaccination in US Veterans who developed new‐onset IIM compared to those without new‐onset IIM.
Caleb Hernández   +10 more
wiley   +1 more source

Imaging of juvenile idiopathic arthritis. Part I: Clinical classifications and radiographs [PDF]

open access: yesJournal of Ultrasonography, 2016
Juvenile idiopathic arthritis is the most common autoimmune systemic disease of the connective tissue affecting individuals at the developmental age. Radiography is the primary modality employed in the diagnostic imaging in order to identify changes ...
Iwona Sudoł-Szopińska   +4 more
doaj   +1 more source

Pain-coping scale for children and their parents: a cross-sectional study in children with juvenile idiopathic arthritis and other causes of musculoskeletal pain [PDF]

open access: gold, 2022
Maria Bäckström   +17 more
openalex   +1 more source

Engineering Immune Cell to Counteract Aging and Aging‐Associated Diseases

open access: yesAdvanced Science, EarlyView.
This review highlights a paradigm shift in which advanced immune cell therapies, initially developed for cancer, are now being harnessed to combat aging. By engineering immune cells to selectively clear senescent cells and remodel pro‐inflammatory tissue microenvironments, these strategies offer a novel and powerful approach to delay age‐related ...
Jianhua Guo   +5 more
wiley   +1 more source

Autoantibody Response Toward Chromatin in Patients With Juvenile Idiopathic Arthritis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Patients with juvenile idiopathic arthritis (JIA) frequently exhibit antinuclear antibodies (ANAs), but the specific antigen target recognized by them and the presence of additional autoantibody specificities in patients with JIA remains elusive.
Viola Pitkänen   +13 more
wiley   +1 more source

Serum Cytokine Profiling Differentiates Underlying Diseases in Cytokine Storm Syndrome

open access: yesArthritis &Rheumatology, EarlyView.
Serum cytokine profiling was performed using Luminex (48 cytokines) and ELISA (5 cytokines). Assessment of key cytokines (IFN‐α, IL‐18, IL‐6, CXCL9) delineated five dominant inflammatory patterns: I, IFN‐α–dominant CSS; II, IL‐18–dominant CSS; III, IL‐6–dominant CSS; IV, IFN‐γ–dominant CSS; and V, IL‐6 & IFN‐γ intermediate CSS.
Shuya Kaneko   +42 more
wiley   +1 more source

Macrophage activation syndrome in a patient with systemic onset of the juvenile idiopathic arthritis

open access: yesRheumatology, 2016
Systemic onset juvenile idiopathic arthritis (sJIA) is defined as arthritis affecting one or more joint usually in the juvenile age group (< 16 years of age) with or preceded by fever of at least 2 weeks duration that is documented to be daily ...
Deepak Jain   +4 more
doaj   +1 more source

Effect of Time to Start of Biologic Therapy on Treatment Response in Childhood Arthritis: Results From the UCAN CAN‐DU Cohort

open access: yesArthritis &Rheumatology, EarlyView.
Objective To estimate the effect of time from symptom onset to start of biologic treatment on achieving inactive arthritis within six months in a cohort of patients with juvenile idiopathic arthritis (JIA). Methods The international UCAN CAN‐DU study prospectively enrolled patients with JIA across Canada and the Netherlands.
Jelleke B. de Jonge   +102 more
wiley   +1 more source

Tocilizumab in the treatment of systemic juvenile idiopathic arthritis

open access: yesOpen Access Rheumatology: Research and Reviews, 2012
Miho Murakami,1 Minako Tomiita,2,3 Norihiro Nishimoto11Laboratory of Immune Regulation, Wakayama Medical University, Wakayama, 2Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, 3Department of Allergy and Rheumatology, Chiba
Murakami M, Tomiita M, Nishimoto N
doaj  

Home - About - Disclaimer - Privacy